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MYOCARDIAL OXYGEN CONSUMPTION
The improvements in cardiac index and left ventricular filling pressure (or pulmonary capillary wedge pressure) seen after bolus injections of 12-5-75 fig kg" 1 of milrinone have been shown to be associated with no significant increase in myocardial oxygen consumption.' 11 '. A clear increase in the ratio of stroke work index to myocardial oxygen consumption, which was statistically significant, has indicated improved left ventricular efficiency. The lack of an increase in myocardial oxygen consumption following milrinone indicates that the peripheral vasodilatation produced reduces the ventricular wall stress and counteracts the increased oxygen requirement which would be necessary to support the enhanced contractility.
Therapeutic benefits from intravenous and oral milrinone
Milrinone, administered either intravenously or orally, produces a clear improvement in maximum exercise capacity. This change occurs acutely and persists for up to 3 months of oral administration' 6 ' 12 '. This is in contrast with the delayed development of improved exercise tolerance seen after administration of the vasodilator angiotensinconverting enzyme (ACE) inhibitor drugs captopril and enalapril' 13 -14 '. This initial observation, which was made in open studies, has been confirmed in the pivotal study described by DiBianco et a/.' 15 '. In this multicentre, placebo-controlled evaluation, patients with NYHA class II or III heart failure received diuretic therapy, were randomly allocated to therapy, for a 3-month period, with either milrinone (10 mg every 6 h), placebo, digoxin, or a combination of milrinone and digoxin. Milrinone prolonged the exercise tolerance time by a mean of 83 s as compared with the placebo response, and this was highly significant. No additional improvement in exercise tolerance was demonstrated when digoxin was given together with milrinone.
It is known from open studies that milrinone increases acutely and chronically the total body oxygen consumption (peak VC^)' 6 ' 7 ' . This has been confirmed in the multicentre, placebo-controlled trial referred to above, in which a sub-group of 60 patients in the randomized trial had peak VO2 measurements taken. There was a statistically significant increase in the peak VO 2 in patients receiving milrinone over a 3-month period (+ 15-3%) as compared with the placebo group (-14-8%). The difference was highly significant' 15 '. It is not clear why milrinone produces an early improvement in exercise tolerance. Studies of limb blood flow have suggested that the increased blood flow demonstrated after amrinone and milrinone administration may indicate improved blood supply to skeletal muscles, thereby delaying the appearance of anaerobic metabolism during exercise' 16 '.
Symptomatic improvement
Both intravenous and oral milrinone have been demonstrated to reduce breathlessness on exertion and at rest, and to improve the symptom of fatigue, as well as reducing peripheral oedema.
In the controlled oral milrinone multicentre study, the quality-of-life assessment made using the sickness impact profile demonstrated significant improvements in the 'sleep and rest' and 'work' categories when patients receiving milrinone were compared with the placebo group' 15 '. There was no change, however, in the NYHA classification of patients receiving milrinone compared with those receiving placebo.
In this study, the need for additional therapy to control heart failure during the trial, including increasing the diuretic dosage (the co-intervention rate), was significantly lower in patients receiving milrinone. This study established that milrinone's effects were maintained throughout the 3 months of treatment and no evidence of tolerance to its action was noted.
Adverse effects
The incidence of adverse effects in the multicentre, oral placebo-controlled study and in a separate invasive haemodynamic study, have been carefully correlated. The only significant side-effects, which have been noted after milrinone administration in controlled studies, are the development of headaches and palpitations in approximately 9% of patients receiving the drug as compared with 3% of patients on placebo. A first-dose effect was observed in a small number of patients receiving milrinone in the controlled exercise tolerance study. This consisted of a small, but statistically significant, fall in the systolic blood pressure of approximately 6% of patients with a non-significant increase in heart rate of approximately 6%, at 60-90 min after drug administration with the patients in the erect posture.
In the multicentre, placebo-controlled milrinone study, 24-h ECG Holter monitoring was carried out in a sub-group of 103 patients. There was no significant difference in the incidence of ventricular arrhythmias between the milrinone, digoxin, milrinone plus digoxin, or placebo groups. However, using the clinical definition of pro-arrhythmia reported by Morganroth' 17 ', there was a marginally greater incidence of pro-arrhythmia in the milrinone-treated patients compared with the placebo group. Proarrhythmia was defined as a 3-to 10-fold increase in the frequency of ventricular premature beats per hour between the baseline and the randomized phase, or a 10-fold increase in repetitive forms of ventricular arrhythmia per hour, or both. Proarrhythmia was observed in nine (18%) patients receiving milrinone as compared with two (4%) patients not receiving milrinone. However, proarrhythmia did not adversely affect clinical outcome' 15 ). Importantly, in view of previous findings with the parent compound amrinone, none of the multicentre controlled or uncontrolled trials of milrinone has shown an increased frequency of gastrointestinal disorders, abnormal liver-function tests or thrombocytopenia.
Survival
Symptomatic improvement in patients with heart failure is an important goal of therapy, particularly in the more severe grades of heart failure. However, the ultimate goal of therapy in all patients with heart failure is, in addition to symptomatic improvement, to enhance survival. The management of heart failure in recent years has been influenced by the recent reports that the ACE inhibitor enalapril has been demonstrated in the Co-operative North Scandinavian Enalapril Survival Study (CONSEN-SUS)' 18 ' to improve survival. Similarly, in the Veterans Administration co-operative study (V-HeFT), the combination of nitrates and hydralazine was shown to improve survival^1 9 '. In order to establish a major therapeutic role, phosphodiesterase inhibitor drugs like milrinone must be shown not only to produce symptomatic improvement, but also to have a beneficial effect on survival.
Experimentally induced congestive heart failure (e.g. by coronary artery ligation in rats) has served as a model for evaluating the effects of milrinone on survival. Milrinone, like enalapril and captopril, has been shown to prolong survival in this rat model of congestive heart failure' 2021 '. No formal controlled clinical mortality/survival study has yet been performed with milrinone. Similarly, open milrinone therapy has not been evaluated over a sufficiently long period of time to produce meaningful estimates of its effect on survival. In this randomized, controlled 3-month trial of milrinone, no clear difference in survival was apparent between patients receiving the drug and those on placebo.
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failure requires further comparative evaluation with established agents. This is particularly important since the publication of the V-HeFT trial and the CONSENSUS trial results' 18 ' 201 . In patients with mild heart failure, in whom symptomatic improvement may be modest, comparative trials are urgently needed to assess the influence of therapy with drugs such as milrinone on survival. A largescale multicentre trial of patients with NYHA class II or III heart failure who are already receiving a diuretic is required. Patients would be randomly allocated to three separate treatment groups (Fig. 3) , and would receive either an ACE inhibitor such as enalapril, or digoxin, or milrinone. In order to demonstrate a 25% reduction in mortality between these groups in such a study, it would be necessary to recruit between 3000 and 4500 patients. Such a study should also monitor changes in quality-of-life indices and exercise tolerance.
Because ACE inhibitors have been shown in the CONSENSUS trial to not only improve symptomatic status, but also survival, treatment with an ACE inhibitor and a diuretic is likely to become the treatment of choice in patients with NYHA class III or IV heart failure. In patients with heart failure it has been clearly demonstrated that haemodynamic improvement is more significant with milrinone than with captopril and that limb blood flow is increased by milrinone but not changed by the ACE inhibitor captopril. The addition of milrinone to captopril therapy increases limb blood flow beneficially' 16 '. This suggests that symptomatic improvements with combined therapy might well be enhanced. A largescale comparative trial in NYHA class III or IV patients is, therefore, desirable in which patients receiving both a diuretic and an ACE inhibitor will be randomly allocated to receive milrinone or placebo therapy (see Fig. 4 ). Again the outcome of such trials using survival, quality-of-life indices and exercisetolerance time should be assessed. Finally, it would be attractive, in view of the results of the V-HeFT study to compare, on a multicentre basis, patients already receiving digoxin and diuretics who would in addition receive therapy with either isosorbide + hydralazine, or an ACE inhibitor, or milrinone.
Conclusion
The phosphodiesterase inhibitor milrinone has been shown to produce clear improvements in systolic and diastolic function following both intravenous and oral administration. This is achieved without a significant increase in myocardial oxygen consumption, because the associated vasodilator action offsets any tendency for an increase in oxygen consumption to be produced by the increase in contractility. In placebo-controlled, double-blind studies, milrinone has been shown to increase exercise tolerance and to improve total body oxygen consumption. Sideeffects are relatively infrequent, although a modest incidence of headache and palpitations in patients receiving milrinone is observed. Ventricular tachyarrhythmias were not significantly increased in placebo-controlled studies of milrinone therapy, but a modest pro-arrhythmic effect may occur. Experimentally, milrinone prolongs survival in a rat heart failure model, but no clinical evidence of prolonged survival following milrinone is currently available. Future large-scale studies of survival and symptomatic response to milrinone are required in patients already receiving a diuretic and an ACE inhibitor.
